We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
How Thermo Fisher Is Riding Bioproduction and AI-Led Growth Trends
Read MoreHide Full Article
Key Takeaways
Thermo Fisher grew bioproduction with 3% organic Life Sciences Solutions growth and a filtration acquisition.
TMO opened a U.S. Bioprocess Design Center to expand customer collaboration and process development.
TMO added Clario's clinical data capabilities as integration and revenue-synergy efforts progressed.
Thermo Fisher Scientific (TMO - Free Report) is building around three growth forces in life sciences: biologic-drug manufacturing, AI-enabled workflows and closer customer collaboration.
These themes can support longer-term expansion, but they also raise the bar. Thermo Fisher must keep launching relevant technologies, integrating acquisitions and proving that scale can translate into better execution.
Year to date, TMO shares have slipped 0.5%, compared with the industry's steeper 11.7% decline.
Image Source: Zacks Investment Research
TMO Expands Its Bioproduction Platform
Bioproduction remained a key growth driver in the second quarter. Demand for tools and services used in biologic-drug development and manufacturing helped Life Sciences Solutions deliver 3% organic growth.
The Solventum filtration and separation acquisition broadens Thermo Fisher’s bioproduction offering across upstream and downstream workflows. Management expects the business to support revenue and cost synergies over time.
Thermo Fisher Brings AI Into Workflows
Thermo Fisher is expanding AI capabilities across its software portfolio. Those tools are designed to support smarter workflows and faster analysis in complex scientific applications.
The company is also applying AI within its PPI Business System. That matters because productivity, quality and customer responsiveness are becoming more important as laboratories handle larger datasets and more integrated workflows.
TMO Deepens Customer Collaboration
Thermo Fisher opened its flagship U.S. Bioprocess Design Center in Massachusetts during the quarter. The site expands its network of customer collaboration centers.
The center allows teams to work with pharma and biotech customers on process development, manufacturing optimization and commercial scale-up. TMO also announced a Singapore precision-health collaboration that combines Olink proteomics with the Orbitrap Astral platform.
Thermo Fisher Advances Clinical Data Capabilities
The Clario acquisition adds digital endpoint data solutions to Thermo Fisher’s portfolio. These capabilities can generate deeper clinical insights and improve drug-development productivity.
Clario also fits with Thermo Fisher’s clinical research business. The business exceeded management’s expectations in the second quarter, while integration remained on track and the revenue-synergy pipeline continued to grow.
TMO Innovation Must Outrun Competition
Competition remains a real constraint. Thermo Fisher operates in markets where technology changes quickly and customer requirements keep evolving.
Rivals can introduce alternative platforms, compete on pricing or bundle products and services more aggressively. That makes timely product launches, customer adoption and acquisition integration essential to sustaining share gains.
Danaher (DHR - Free Report) and Agilent Technologies (A - Free Report) remain relevant peers for investors watching innovation in life sciences tools, diagnostics and laboratory technologies. Danaher describes itself as a life sciences and diagnostics innovator, while Agilent supplies application-focused solutions across life sciences, diagnostics and applied chemical markets.
Thermo Fisher Momentum Supports the Trend Story
The bottom line is that Thermo Fisher is aligned with attractive life-science trends, especially bioproduction, AI-led workflow improvement and clinical data capabilities. The case depends on execution as much as market demand.
Here’s how Thermo Fisher’s five-year sales multiple looks like compared to the industry average.
Image Source: Zacks Investment Research
TMO currently carries a Zacks Rank #3 (Hold). That indicates the long-term technology and demand themes have not yet translated into a stronger short-term rating.
The Momentum Score of A is encouraging because it points to favorable near-term trading characteristics. However, the Value Score, Growth Score and VGM Score of C call for measured expectations, especially after the stock’s recent earnings-driven support.
View the Zacks #1 Rank List
Image: Bigstock
How Thermo Fisher Is Riding Bioproduction and AI-Led Growth Trends
Key Takeaways
Thermo Fisher Scientific (TMO - Free Report) is building around three growth forces in life sciences: biologic-drug manufacturing, AI-enabled workflows and closer customer collaboration.
These themes can support longer-term expansion, but they also raise the bar. Thermo Fisher must keep launching relevant technologies, integrating acquisitions and proving that scale can translate into better execution.
Year to date, TMO shares have slipped 0.5%, compared with the industry's steeper 11.7% decline.
Image Source: Zacks Investment Research
TMO Expands Its Bioproduction Platform
Bioproduction remained a key growth driver in the second quarter. Demand for tools and services used in biologic-drug development and manufacturing helped Life Sciences Solutions deliver 3% organic growth.
The Solventum filtration and separation acquisition broadens Thermo Fisher’s bioproduction offering across upstream and downstream workflows. Management expects the business to support revenue and cost synergies over time.
Thermo Fisher Brings AI Into Workflows
Thermo Fisher is expanding AI capabilities across its software portfolio. Those tools are designed to support smarter workflows and faster analysis in complex scientific applications.
The company is also applying AI within its PPI Business System. That matters because productivity, quality and customer responsiveness are becoming more important as laboratories handle larger datasets and more integrated workflows.
TMO Deepens Customer Collaboration
Thermo Fisher opened its flagship U.S. Bioprocess Design Center in Massachusetts during the quarter. The site expands its network of customer collaboration centers.
The center allows teams to work with pharma and biotech customers on process development, manufacturing optimization and commercial scale-up. TMO also announced a Singapore precision-health collaboration that combines Olink proteomics with the Orbitrap Astral platform.
Thermo Fisher Advances Clinical Data Capabilities
The Clario acquisition adds digital endpoint data solutions to Thermo Fisher’s portfolio. These capabilities can generate deeper clinical insights and improve drug-development productivity.
Clario also fits with Thermo Fisher’s clinical research business. The business exceeded management’s expectations in the second quarter, while integration remained on track and the revenue-synergy pipeline continued to grow.
TMO Innovation Must Outrun Competition
Competition remains a real constraint. Thermo Fisher operates in markets where technology changes quickly and customer requirements keep evolving.
Rivals can introduce alternative platforms, compete on pricing or bundle products and services more aggressively. That makes timely product launches, customer adoption and acquisition integration essential to sustaining share gains.
Danaher (DHR - Free Report) and Agilent Technologies (A - Free Report) remain relevant peers for investors watching innovation in life sciences tools, diagnostics and laboratory technologies. Danaher describes itself as a life sciences and diagnostics innovator, while Agilent supplies application-focused solutions across life sciences, diagnostics and applied chemical markets.
Thermo Fisher Momentum Supports the Trend Story
The bottom line is that Thermo Fisher is aligned with attractive life-science trends, especially bioproduction, AI-led workflow improvement and clinical data capabilities. The case depends on execution as much as market demand.
Here’s how Thermo Fisher’s five-year sales multiple looks like compared to the industry average.
Image Source: Zacks Investment Research
TMO currently carries a Zacks Rank #3 (Hold). That indicates the long-term technology and demand themes have not yet translated into a stronger short-term rating.
The Momentum Score of A is encouraging because it points to favorable near-term trading characteristics. However, the Value Score, Growth Score and VGM Score of C call for measured expectations, especially after the stock’s recent earnings-driven support.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.